Promoting Better Clinical Trials and Drug Information as Public Health Interventions for the COVID-19 Emergency in Italy
- PMID: 32543882
- PMCID: PMC7322772
- DOI: 10.7326/M20-3775
Promoting Better Clinical Trials and Drug Information as Public Health Interventions for the COVID-19 Emergency in Italy
Abstract
According to these authors from the Italian Medicines Agency, “evidence-informed prescribing and clinical trials were beaten off the mark by social media, rumors, and panic in the early phase of the COVID-19 pandemic.” In this article, they describe lessons learned to counteract misleading information and nudge the research community to do high-quality, informative multigroup trials.
References
-
- Kalil AC. Treating COVID-19—off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA. 2020. [PMID: 32208486] doi:10.1001/jama.2020.4742. - PubMed
-
- Rome BN, Avorn J. Drug evaluation during the Covid-19 pandemic. N Engl J Med. 2020;382:2282-2284. [PMID: 32289216] doi:10.1056/NEJMp2009457. - PubMed
-
- London AJ, Kimmelman J. Against pandemic research exceptionalism. Science. 2020;368:476-477. [PMID: 32327600] doi:10.1126/science.abc1731. - PubMed
-
- Decreto Legge Cura Italia Art. 17. Disposizioni urgenti materia di sperimentazione dei medicinali e dispositivi medici per l'emergenza epidemiologica da COVID. Gazzetta Ufficiale (serie generale n.70 del 17-03-2020). Accessed at www.gazzettaufficiale.it/eli/gu/2020/03/17/70/sg/pdf. on 16 June 2020.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical